AstraZeneca agreed to pay a $560,000 settlement to resolve allegations of gender and racial discrimination filed by employees at the company’s Wilmington, Del. headquarters.
As the fraud trial of Theranos founder Elizabeth Holmes headlines the pharma legal news, other court-related cases are taking place, including a ruling in the legal spat between Takeda and AbbVie over a supply agreement for the prostate cancer drug Lupron.
St. Jude Medical, which was acquired by Abbott Laboratories in 2017, agreed to pay $27 million to settle allegations the company knowingly sold defective heart devices, the U.S. Justice Department said on July 8.
Moncef Slaoui, who served as chief scientist for the Operation Warp Speed response to the Covid-19 pandemic under former President Donald Trump, was fired as chairman of the board of directors of Galvani Bioelectronics following the “substantiation” of allegations of sexual harassment and inappropriate conduct.
A U.S. judge granted a Reuters request to unseal Merck & Co. documents produced in lawsuits related to the company’s anti-baldness treatment Propecia, finding that the public’s right to access outweighed the drug maker’s arguments for keeping the information secret.
Biogen Inc. agreed to pay $22 million to resolve U.S. allegations that the company illegally used two charities that help cover Medicare patients’ out-of-pocket drug costs as a means to pay them kickbacks to use the Cambridge, Mass-based drugmaker’s multiple sclerosis medicines.
Johnson & Johnson will contribute up to $1 billion more to a potential settlement of lawsuits alleging the New Brunswick, New Jersey-based drugmaker and other companies fueled the U.S. opioid epidemic, bringing J&J’s total payment to $5 billion.
Advanced Care Scripts Inc. will pay $3.5 million to resolve allegations that the Florida-based specialty pharmacy served as a conduit for a Teva Pharmaceutical Industries Ltd. subsidiary to pay kickbacks to Medicare patients, the U.S. Justice Department said.
The Australian Competition and Consumer Commission said the ACCC is taking local units of GlaxoSmithKline and Swiss healthcare company Novartis to court over false or misleading representations in the marketing of pain relief products.
A large group of U.S. states accused key players in the generic drug industry of a broad price-fixing conspiracy, moving to widen an earlier lawsuit to add many more drugmakers and medicines in an action that sent some company shares tumbling.